Bumecard 5 Tablet
Bumetanide
5mg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 18.00 AED |
Available as:
Indications
Bumecard 5 Tablet is used for:
Oedema, Heart failure, Hypertension, Nephrotic syndrome
Adult Dose
Oral
Oedema
Edema due to congestive heart failure, hepatic disease, or nephrotic syndrome
Adult: 1 mg once daily. Give 2nd dose 6-8 hr later if necessary.
Refractory edema
Adult: Initially, 5 mg daily was increased by 5 mg every 12-24 hr as required. High doses may be divided in 2-3 doses. Max: 10 mg/day.
Hypertension
Adult: 0.5-1 mg daily. Max: 5 mg/day.
Parenteral
Emergency cases of edema
Adult: 0.5-1 mg via slow IV/IM inj, subsequently adjust dose according to the response.
Intravenous
Pulmonary edema
Adult: 1-2 mg IV repeated 20 min later if necessary, or 2-5 mg in 500 ml of a suitable infusion fluid given over 30-60 min.
Child Dose
Renal Dose
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
IV/IM Administration
May be administered by IM injection, by IV injection over 1-2 minutes, or by IV infusion
Contra Indications
Hypersensitivity, progressive renal failure and anuria, hepatic coma, severe electrolyte depletion.
Precautions
Agent is a potent diuretic that, if given in excessive amounts, may lead to a profound diuresis with water and electrolyte depletion
Careful medical supervision is required; dosing must be adjusted to the patient's needs
Risk of electrolyte imbalance, alterations in glucose metabolism, blood dyscrasias, development of oliguria or increased blood urea nitrogen (BUN) or creatinine, hepatic disease, hyperuricemia, hypomagnesemia, hypovolemia, neonates at risk for kernicterus
Hypokalemia may occur; close medical supervision and dose evaluation required; may need potassium supplementation and/or use of potassium-sparing diuretics to prevent hypokalemia; loop diuretics can also decrease serum calcium levels; electrolyte disturbances can predispose a patient to serious cardiac arrhythmias
Risk of ototoxicity with rapid IV administration
Fluid status and renal function should be monitored to prevent oliguria, increased creatinine and BUN, and azotemia
Avoid use in neonates at risk for kernicterus; drug is a potent displacer of bilirubin in neonates
If given the morning of surgery, drug may render patient volume depleted and blood pressure may be labile during general anesthesia
Use with caution in patients with cirrhosis
Coadministration with antihypertensive agent may increase risk of hypotension
Monitoring Parameters
Regular monitoring of serum electrolytes (especially potassium, calcium, magnesium).
Monitor blood glucose, BUN, creatinine levels as well as blood counts.
Pregnancy-Lactation
Pregnancy category: C
Lactation: Unknown whether drug is excreted in breast milk; use with caution
Interactions
Reduced diuretic and natriuretic actions by probenecid. Indometacin blunts action of bumetanide; concurrent usage with antihypertensives may increase risk of orthostatic hypotension.
Potentially Fatal: Avoid concurrent usage with ototoxic drugs such as aminoglycoides and nephrotoxic drugs. Reduced lithium excretion via kidneys.
Contraindicated (0)
Serious (8)
amikacin
gentamicin
lofexidine
neomycin PO
paromomycin
squill
streptomycin
tobramycin
Adverse Effects
Side effects of Bumetanide :
>10%
Hyperuricemia (18%),Hypochloremia (15%),Hypokalemia (15%),Azotemia (11%)
1-10%
Hyponatremia (9%),Hyperglycemia (7%),Increased serum creatinine (7%),Variations in phosphorus (5%),Variations in CO2 content (4%),Variations in bicarbonate (3%),Variations in calcium (2%),Dizziness (1%),Muscle cramps (1%),Ototoxicity (1%)
<1%
Asterixis,Dehydration,Hypotension,Orthostatic hypotension,Pruritus,Rash,Renal failure,Serious skin reactions (ie, Stevens-Johnson syndrome, toxic epidermal necrolysis),Vertigo,Vomiting
Potentially Fatal: Encephalopathy (in patients with preexisting liver disease).
Mechanism of Action
Bumetanide induces diuresis by inhibiting reabsorption of water and electrolytes (sodium and chloride) in the ascending loop of Henle and proximal renal tubule.
Note
Bumecard 5 5mg Tablet manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Bumetanide. Bumecard 5 is availble in Bangladesh.
Farmaco BD drug index information on Bumecard 5 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.